See your weight loss results.

In the clinical trials that supported FDA approval of the branded products, average weight loss ranged from roughly 15% of body weight with semaglutide (Wegovy®) to about 20–22% with tirzepatide (Zepbound®) over 68–72 weeks at the highest doses. Those figures describe the branded products, not compounded preparations, and individual results vary with dose, diet, activity, and adherence. This calculator gives an estimate, not a guarantee.

Most guidelines consider about 1–2 pounds (roughly 0.5–1 kg) per week to be a safe, sustainable rate. GLP-1 medications are titrated up gradually over several weeks, so weight loss usually starts slowly and builds as the dose increases. Faster is not better — gradual loss helps preserve muscle and is easier to maintain.

Some weight regain is common after stopping a GLP-1, because the medication's appetite effects end when treatment ends. Many people maintain results by continuing a lower maintenance dose and keeping the nutrition and activity habits built during treatment. Your licensed provider can help plan a long-term, sustainable approach.

No. This tool gives a general estimate for educational purposes only and is not medical advice or a treatment recommendation. Whether a GLP-1 medication is appropriate for you is a decision made with a licensed provider after reviewing your full health history.